The lymphatic vasculature plays an important role in mediating fluid balance and local inflammation in many tissues and organs throughout the body (Huang et al., 2017; Oliver et al., 2020). The heart also carries a complex lymphatic network and relies on cardiac lymphatics to drain interstitial fluids and immune cells for maintaining homeostasis (Brakenhielm and Alitalo, 2019). Disrupting cardiac lymphatics can cause myocardial edema and lead to impaired cardiac function (Cui et al., 2001; Mehlhorn et al., 1995), indicating a critical role of cardiac lymphatics in cardiovascular physiology. Recently, cardiac lymphatics have emerged as a new therapeutic target for acute cardiac injuries. Several studies have demonstrated using rodent models that therapeutic lymphangiogenesis reduced myocardial edema and fibrosis, resolved inflammation, and improved cardiac function after myocardial infarction (Henri et al., 2016; Houssari et al., 2020; Klotz et al., 2015; Tatin et al., 2017; Trincot et al., 2019; Vieira et al., 2018) or ischemia and reperfusion injury (Shimizu et al., 2018). These studies in aggregate concluded that the improvement in cardiac function was due to local proliferation of lymphatic vessels at the site of injury in response to lymphangiogenic therapies. Importantly, these animal models represent cardiac injuries, in which blood and lymphatic vessels are surgically manipulated. However, the role of the lymphatic vasculature in the pathogenesis of chronic cardiac dysfunction and the effects of lymphangiogenic therapies on cardiac dysfunction remain to be explored. Here, we explored the role of the lymphatic vasculature in cardiac dysfunction and investigated the effects of a lymphangiogenic therapy (VEGFCc156s) on the angiotensin II infusion-induced cardiac dysfunction model. We found that angiotensin II infusion-induced cardiac dysfunction is associated with impaired lymphatic vascular function as well as increased cardiac fibrosis and inflammation, whereas VEGFCc156s treatment ameliorated these pathologies. Interestingly, angiotensin II-infused mice treated with VEGFCc156s also demonstrated a delayed and dramatic response to reverse angiotensin II-induced hypertension. Thus, we propose that the beneficial effects of the lymphangiogenic therapy VEGFCc156s on angiotensin II infusion-induced cardiac dysfunction are multifaceted and mediated by its concomitant effects on cardiac lymphatic function, inflammatory and fibrotic gene expression, and systemic hypertension.

Recent studies indicated that the lymphatic vasculature, a traditionally-neglected target for therapeutic interventions, plays an important role in the pathogenesis of cardiovascular diseases, and enhancing lymphangiogenesis could be beneficial for acute cardiac injuries (Henri et al., 2016; Houssari et al., 2020; Huang et al., 2017; Klotz et al., 2015; Liu and Oliver, 2019; Shimizu et al., 2018; Tatin et al., 2017; Trincot et al., 2019; Vieira et al., 2018; Vivien et al., 2019). However, the role of the lymphatic vasculature in chronic cardiac dysfunction remains to be elucidated. In this study, we aimed to investigate the role of the lymphatic vasculature in the pathogenesis of chronic heart failure and cardiac dysfunction. We found several SNPs near lymphatic marker gene loci that were associated with human cardiovascular or metabolic comorbidities in human GWAS studies, although some of the associations did not meet the genome-wide threshold and some of the loci are close to another gene in addition to the lymphatic endothelial marker (Table 1). To validate the findings from the GWAS analysis, we conducted expression profiling using human heart samples and found reduced expression of lymphatic endothelial markers in human chronic heart failure hearts (Figure 1), suggesting that the lymphatic vasculature may play a role in the pathogenesis of human chronic heart failure and cardiac dysfunction. Our observations are in line with previously published RNA sequencing analyses of human hearts (Sweet et al., 2018; van Heesch et al., 2019) and a recent clinical report indicating that serum VEGFC levels are significantly and inversely associated with all-cause and cardiovascular death (Wada et al., 2018), supporting a role of lymphatic vasculature in the pathogenesis of cardiovascular diseases. However, previous reports found minimal changes in lymphatic vascular density in left ventricular endomyocardial biopsies from terminal heart failure hearts and healthy donor hearts using immunohistochemistry (Dashkevich et al., 2009; Dashkevich et al., 2010). Thus, further investigations are required to characterize the changes in lymphatic vasculature in human chronic heart failure pathogenesis.

Using a murine model of cardiac dysfunction, we demonstrate that a chronic cardiac insult such as angiotensin II infusion induced lymphatic vascular dysfunction by reducing lymphatic vascular density (Figure 2) and impairing lymphatic vascular transport function in the heart (Figure 3). Podoplanin is widely used as a marker for LECs and is preferentially expressed in pre-collectors and collectors of the cardiac lymphatic vasculature (Henri et al., 2016). A previous study demonstrated that enhancing lymphangiogenesis by over-expressing VEGFC with adenoviruses in a mouse model of lymphedema induced robust growth of lymphatic capillaries in axillary tissues after 2 weeks but failed to improve lymphatic vascular leakage, while with prolonged VEGFC stimulation (2–6 months), the lymphatic capillaries underwent an intrinsic remodeling and maturation and became functional collecting vessels, leading to reduced tissue edema and restored lymphatic drainage (Norrmén et al., 2011; Tammela et al., 2007). Moreover, VEGFCc156s can reportedly directly enhance lymphatic pump activity and lymphatic output in rat mesentery collecting lymphatics (Breslin et al., 2007), indicating a potential direct beneficial effect of VEGFCc156s on lymphatic vascular function in addition to its role in enhancing lymphangiogenesis and maturation. Here, consistent with these previous reports, we observed that 6 week continuous infusion of VEGFCc156s concomitant with angiotensin II restored collecting vessel function and improved cardiac lymphatic drainage, leading to improved cardiac fluid balance regulation. Myocardial edema is a key clinical feature of cardiac dysfunction and chronic heart failure, and heart function could be significantly compromised with a subtle increase in interstitial fluid volume (Dongaonkar et al., 2010). Therefore, the improved cardiac lymphatic vascular function and tissue fluid homeostasis in the VEGFCc156s-treated, angiotensin II-infused animals might contribute to the improved cardiac function and reduced cardiac hypertrophy observed. One area for future investigation is a further characterization of the changes in cardiac lymphatic valves, which play an important role in regulating the lymph flow in collecting vessels. In addition, podoplanin, a marker of lymphatic collecting vessels, is also reportedly expressed in inflammatory cells. Previous reports indicated that a high frequency of podoplanin-expressing cells appeared in the infarcted heart and facilitated local inflammation, and podoplanin neutralization improved cardiac function after myocardial infarction (Cimini et al., 2017; Cimini et al., 2019; Quintanilla et al., 2019). In our study, we assessed podoplanin-expressing lymphatic vessels but not other podoplanin-expressing cells; further analysis of other podoplanin-expressing cells in our disease model would be an area for future investigation.

Previous studies have demonstrated impairments in the lymphatic vasculature in a myocardial infarction model, where the left anterior descending artery is surgically ligated (Henri et al., 2016; Klotz et al., 2015). Importantly, the lymphatic vessel parallel to this major blood vessel is likely also mechanically impaired by this surgical manipulation, thus testing the hypothesis that mechanical disruption of the lymphatic vasculature can impair heart function, and regrowth using lymphangiogenic therapy is beneficial. Our observations are in line with these previous studies; however, the studies presented herein importantly assess lymphatic dysfunction in the absence of direct injury or surgical manipulation. Likely the impairments in lymphatic vascular function observed in angiotensin II-infused mice could come directly from angiotensin II actions on the endothelium, as angiotensin II can induce endothelial dysfunction (Gomolak and Didion, 2014; Watanabe et al., 2005) or perhaps indirectly from angiotensin II infusion-induced hypertension, which reportedly alters lymphatic vascular function (Dongaonkar et al., 2015).

The lymphatic vasculature also plays an important role in mediating local inflammation (Brakenhielm and Alitalo, 2019), and in acute cardiac injury models, resolution of inflammation following lymphangiogenic therapy has been proposed to be an underlying therapeutic mechanism (Tatin et al., 2017; Vieira et al., 2018). Our RNA-seq analysis indicated that LECs expressed proinflammatory chemokines after angiotensin II stimulation (Figure 4), which is consistent with previous reports indicating a role of angiotensin II in initiating inflammatory and chemotactic responses in tissues and vasculature (Benigni et al., 2010; Suzuki et al., 2003). Interestingly, VEGFCc156s treatment alleviated the inflammatory responses induced by angiotensin II infusion in LECs by reducing the expression of proinflammatory chemokines, which may contribute to the beneficial effects of VEGFCc156s on angiotensin II-induced cardiac dysfunction. Our results are in line with a previous report indicating that VEGFCc156s treatment downregulated the expression of genes involved in immune regulation and inflammation in dermal LECs without stress or stimulation (Dieterich et al., 2017), while here we report that VEGFCc156s treatment ameliorated inflammatory responses in LECs under stress (angiotensin II infusion). Moreover, the transcriptional changes in LECs detected by RNA-seq analysis translated to tissue and systemic levels, and we observed elevations in chemokine levels in skin and plasma in angiotensin II-infused mice, which were alleviated by VEGFCc156s treatment. These results in aggregate suggest that lymphatic vessels may play a more active role in mediating local and systemic inflammation than simply providing a route for immune cell clearance, and VEGFCc156s may directly alleviate systemic inflammation through transcriptional effects on LECs.

More interestingly, upon VEGFCc156s treatment, a significant reduction of angiotensin II-induced increases in blood pressure and kidney damage was observed (Figure 5 and Figure 6). Our observations are in line with a previous report indicating that the treatment of VEGFC, a ligand for both VEGFR2 and VEGFR3, also induced a delayed systemic hemodynamic response to reduce blood pressure and attenuated related renal damage in a high-salt induced hypertension model (Beaini et al., 2019). Our study used VEGFCc156s, a ligand with specificity for VEGFR3, suggesting that VEGFC-mediated effects are indeed mediated by VEGFR3 activation. Furthermore, these effects are not limited to salt-induced pathology, as VEGFCc156s also ameliorated angiotensin II-induced hypertension and renal damage, suggesting that VEGFC may play a broad role to modulate hypertension. Moreover, in line with the observations using the murine models, a recent clinical study also showed that patients with hypertension have significantly lower serum VEGFC levels compared with healthy individuals (Chachaj et al., 2018), supporting a potential role of lymphatic vasculature in the pathogenesis of human hypertension. Hypertension is a major risk factor for heart failure and other cardiovascular diseases (Dorans et al., 2018; Tackling and Borhade, 2019), and anti-hypertensive therapies significantly reduce cardiovascular events and mortality in patients in clinical studies (Ettehad et al., 2016). Therefore, the effect of VEGFCc156s on blood pressure might also contribute significantly to its beneficial effects on angiotensin II-induced cardiac dysfunction.

Consistent with previous reports regarding the role of renal lymphatics in the pathogenesis of hypertension (Balasubbramanian et al., 2020; Lopez Gelston et al., 2018), we also observed an endogenous expansion of renal lymphatics in response to angiotensin II-induced hypertension (Figure 6). The previous reports also demonstrated that enhancing renal lymphatic expansion by over-expressing VEGFD prevented the development of hypertension. Therefore, we initially hypothesized that VEGFCc156s might enhance the endogenous renal lymphangiogenesis response and thus ameliorate angiotensin II infusion-induced hypertension. Surprisingly, no lymphangiogenic response was observed in the kidney of VEGFCc156s-treated angiotensin II-infused animals at both the 1-week and 6-week time points assessed here (Figure 6E and F, Figure 6—figure supplement 1E–1H and Figure 7—figure supplement 1F–1H). Thus, it is possible that the lymphangiogenesis response we observed in the kidney of angiotensin II-infused mice could be an adaptation to hypertension and was therefore ameliorated in VEGFCc156s-treated, angiotensin II-infused mice at the 6-week timepoint due to reduced blood pressure. In the previous reports, the authors used a transgenic line to over-express VEGFD by 800-fold over baseline specifically in kidney and observed significant expansion of renal lymphatics, while our study used VEGFCc156s at a low dose that only increased plasma VEGFC levels by 1.6-fold to 1.9-fold on average. In addition, as a low-molecular weight protein, VEGFCc156s will be quickly filtered through glomeruli followed by adsorptive endocytosis and lysosomal degradation (Franssen et al., 1994), resulting in poor local retention and exposure of VEGFCc156s in kidney. Therefore, the discrepancy between our study and previous studies could possibly be explained by differences in local exposure of the lymphangiogenic factors with transgenic overexpression and chronic systemic administration.

Although VEGFCc156s significantly ameliorated angiotensin II-induced hypertension, the underlying molecular mechanisms remain to be explored. We first carefully examined the possibility that VEGFCc156s interfered with angiotensin II-mediated effects, and several lines of evidence in our studies indicate that there were no alterations in angiotensin II-mediated vascular effects after VEGFCc156s treatment, as angiotensin II caused aortic remodeling (Figure 5F), induced vascular leakage (Figure 3B) and vascular hypertrophy (Figure 6—figure supplement 1A) and increased renal Ace2 expression (Figure 5G and Figure 7—figure supplement 1D) similarly in both the angiotensin II-infused and the VEGFCc156s-treated, angiotensin II-infused group, indicating that angiotensin II acted as a vasoactive molecule in both groups. In addition, causal reasoning analysis of RNA-seq data also pointed at angiotensin II as a causal factor for the changes observed in cardiomyocytes from both the angiotensin II-infused and the VEGFCc156s-treated, angiotensin II-infused group. Finally, the similar blood pressure elevations detected in the first week in both angiotensin II-infused and VEGFCc156s-treated, angiotensin II-infused groups indicated successful release of angiotensin II from the pumps in both groups (Figure 5). Therefore, we suggest that VEGFCc156s did not interfere with angiotensin II effects to alleviate the phenotypes in this disease model. Another possibility is that VEGFCc156s might affect the skin lymphatic vasculature to regulate blood pressure, as skin lymphatics have been implicated as a potential disease-modifying factor in the pathogenesis of salt-sensitive hypertension (Karlsen et al., 2018). After 6 weeks of treatment, VEGFCc156s significantly increased skin lymphatic vessel density and diameter in angiotensin II-infused mice (Figure 2—figure supplement 1O–1R); these changes may contribute to the reductions observed in blood pressure in these animals. Further investigations are needed to fully characterize the molecular mechanisms underlying the beneficial effect of VEGFCc156s on angiotensin II-induced hypertension.

To dissect the potential direct effect of VEGFCc156s on the heart from its effect on blood pressure, we examined the effects of VEGFCc156s in angiotensin II-infused mice at 1 week after treatment, at which timepoint the blood pressure was similarly high in animals treated with angiotensin II alone or a combination of angiotensin II and VEGFCc156s (Figure 5). Although VEGFCc156s treatment enhanced podoplanin-positive lymphatic vessel growth in the heart at this timepoint, it did not alleviate cardiac hypertrophy in angiotensin II-infused mice. More interestingly, VEGFCc156s treatment restored angiotensin II-induced pro-fibrotic and pro-inflammatory markers in angiotensin II-infused hearts in gene expression analyses and immunohistochemistry staining, indicating a beneficial effect of VEGFCc156s in a blood pressure-independent manner (Figure 7 and Figure 7—figure supplements 1 and 2). The lymphatic vasculature has been proposed to play an important role in regulating myocardial fibrosis (Brakenhielm et al., 2020) and a previous report indicated that lymphangiogenic factor treatment in a rat model of myocardial infarction improved cardiac function by reducing cardiac fibrosis (Henri et al., 2016). Our results are in line with this previous report, as VEGFCc156s also reduced cardiac fibrosis in angiotensin II-infused mice as early as 1 week post-treatment, which may contribute to the efficacy we observed at the 6-week timepoint.

In summary, our study demonstrates that lymphatic vessels are impaired in cardiac dysfunction, and the lymphangiogenic therapy VEGFCc156s prevented cardiac dysfunction by improving lymphatic vascular function, alleviating cardiac fibrosis and inflammation, and ameliorating hypertension. These results provide new insights into the potential effects of a lymphangiogenic therapy on chronic cardiac diseases and underlying mechanisms and indicate that the lymphatic vasculature could be a therapeutic target for hypertension and hypertensive heart disease.

RNA-Seq data has been deposited in GEO under accession code GSE150041. All other data generated during the study are included in the manuscript and supporting files. Source data has been provided for Figure 1-7.

1. 1. Song L
   2. Shipstone A
   3. Nagle MW

   (2020) NCBI Gene Expression Omnibus

   ID GSE150041. RNA sequencing study using Prox1-eGFP mice to investigate the role of lymphatic vasculature in chronic cardiac dysfunction.

   https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150041

1. 1. Atsma F
   2. Veldhuizen I
   3. de Kort W
   4. van Kraaij M
   5. Pasker-de Jong P
   6. Deinum J

   (2012) Hemoglobin level is positively associated with blood pressure in a large cohort of healthy individuals

   Hypertension 60:936–941.

   https://doi.org/10.1161/HYPERTENSIONAHA.112.193565

   • PubMed
   • Google Scholar
2. 1. Balasubbramanian D
   2. Gelston CAL
   3. Lopez AH
   4. Iskander G
   5. Tate W
   6. Holderness H
   7. Rutkowski JM
   8. Mitchell BM

   (2020) Augmenting renal lymphatic density prevents angiotensin II-Induced hypertension in male and female mice

   American Journal of Hypertension 33:61–69.

   https://doi.org/10.1093/ajh/hpz139

   • PubMed
   • Google Scholar
3. 1. Beaini S
   2. Saliba Y
   3. Hajal J
   4. Smayra V
   5. Bakhos JJ
   6. Joubran N
   7. Chelala D
   8. Fares N

   (2019) VEGF-C attenuates renal damage in salt-sensitive hypertension

   Journal of Cellular Physiology 234:9616–9630.

   https://doi.org/10.1002/jcp.27648

   • PubMed
   • Google Scholar
4. 1. Benigni A
   2. Cassis P
   3. Remuzzi G

   (2010) Angiotensin II revisited: new roles in inflammation, immunology and aging

   EMBO Molecular Medicine 2:247–257.

   https://doi.org/10.1002/emmm.201000080

   • Google Scholar
5. 1. Brakenhielm E
   2. González A
   3. Díez J

   (2020) Role of cardiac lymphatics in myocardial Edema and Fibrosis: JACC Review Topic of the Week

   Journal of the American College of Cardiology 76:735–744.

   https://doi.org/10.1016/j.jacc.2020.05.076

   • PubMed
   • Google Scholar
6. 1. Brakenhielm E
   2. Alitalo K

   (2019) Cardiac lymphatics in health and disease

   Nature Reviews Cardiology 16:56–68.

   https://doi.org/10.1038/s41569-018-0087-8

   • Google Scholar
7. 1. Breslin JW
   2. Gaudreault N
   3. Watson KD
   4. Reynoso R
   5. Yuan SY
   6. Wu MH

   (2007) Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism

   American Journal of Physiology-Heart and Circulatory Physiology 293:H709–H718.

   https://doi.org/10.1152/ajpheart.00102.2007

   • PubMed
   • Google Scholar
8. 1. Briguet A
   2. Courdier-Fruh I
   3. Foster M
   4. Meier T
   5. Magyar JP

   (2004) Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse

   Neuromuscular Disorders 14:675–682.

   https://doi.org/10.1016/j.nmd.2004.06.008

   • PubMed
   • Google Scholar
9. 1. Caillon A
   2. Paradis P
   3. Schiffrin EL

   (2019) Role of immune cells in hypertension

   British Journal of Pharmacology 176:1818–1828.

   https://doi.org/10.1111/bph.14427

   • PubMed
   • Google Scholar
10. 1. Chachaj A
    2. Puła B
    3. Chabowski M
    4. Grzegrzółka J
    5. Szahidewicz-Krupska E
    6. Karczewski M
    7. Janczak D
    8. Dzięgiel P
    9. Podhorska-Okołów M
    10. Mazur G
    11. Gamian A
    12. Szuba A

    (2018) Role of the lymphatic system in the pathogenesis of hypertension in humans

    Lymphatic Research and Biology 16:140–146.

    https://doi.org/10.1089/lrb.2017.0051

    • PubMed
    • Google Scholar
11. 1. Chindelevitch L
    2. Ziemek D
    3. Enayetallah A
    4. Randhawa R
    5. Sidders B
    6. Brockel C
    7. Huang ES

    (2012) Causal reasoning on biological networks: interpreting transcriptional changes

    Bioinformatics 28:1114–1121.

    https://doi.org/10.1093/bioinformatics/bts090

    • PubMed
    • Google Scholar
12. 1. Cimini M
    2. Cannatá A
    3. Pasquinelli G
    4. Rota M
    5. Goichberg P

    (2017) Phenotypically heterogeneous podoplanin-expressing cell populations are associated with the lymphatic vessel growth and fibrogenic responses in the acutely and chronically infarcted myocardium

    PLOS ONE 12:e0173927.

    https://doi.org/10.1371/journal.pone.0173927

    • PubMed
    • Google Scholar
13. 1. Cimini M
    2. Garikipati VNS
    3. de Lucia C
    4. Cheng Z
    5. Wang C
    6. Truongcao MM
    7. Lucchese AM
    8. Roy R
    9. Benedict C
    10. Goukassian DA
    11. Koch WJ
    12. Kishore R

    (2019) Podoplanin neutralization improves cardiac remodeling and function after acute myocardial infarction

    JCI Insight 5:e126967.

    https://doi.org/10.1172/jci.insight.126967

    • Google Scholar
14. 1. Cui Y
    2. Urschel JD
    3. Petrelli NJ

    (2001) The effect of cardiopulmonary lymphatic obstruction on heart and lung function

    The Thoracic and Cardiovascular Surgeon 49:35–40.

    https://doi.org/10.1055/s-2001-9917

    • PubMed
    • Google Scholar
15. 1. Dashkevich A
    2. Bloch W
    3. Antonyan A
    4. Fries JU
    5. Geissler HJ

    (2009) Morphological and quantitative changes of the initial myocardial lymphatics in terminal heart failure

    Lymphatic Research and Biology 7:21–27.

    https://doi.org/10.1089/lrb.2008.1010

    • PubMed
    • Google Scholar
16. 1. Dashkevich A
    2. Bloch W
    3. Antonyan A
    4. Goebel H
    5. Fries JU
    6. Schlensak C
    7. Beyersdorf F
    8. Geissler HJ

    (2010)

    Immunohistochemical study of remodeling of myocardial lymphatic and blood microvascular structures in terminal heart failure: differences between ischemic and dilated cardiomyopathy

    Lymphology 43:110–117.

    • PubMed
    • Google Scholar
17. 1. Dieterich LC
    2. Ducoli L
    3. Shin JW
    4. Detmar M

    (2017) Distinct transcriptional responses of lymphatic endothelial cells to VEGFR-3 and VEGFR-2 stimulation

    Scientific Data 4:170106.

    https://doi.org/10.1038/sdata.2017.106

    • PubMed
    • Google Scholar
18. 1. Dongaonkar RM
    2. Stewart RH
    3. Geissler HJ
    4. Laine GA

    (2010) Myocardial microvascular permeability, interstitial oedema, and compromised cardiac function

    Cardiovascular Research 87:331–339.

    https://doi.org/10.1093/cvr/cvq145

    • PubMed
    • Google Scholar
19. 1. Dongaonkar RM
    2. Nguyen TL
    3. Quick CM
    4. Heaps CL
    5. Hardy J
    6. Laine GA
    7. Wilson E
    8. Stewart RH

    (2015) Mesenteric lymphatic vessels adapt to mesenteric venous hypertension by becoming weaker pumps

    American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 308:R391–R399.

    https://doi.org/10.1152/ajpregu.00196.2014

    • PubMed
    • Google Scholar
20. 1. Dorans KS
    2. Mills KT
    3. Liu Y
    4. He J

    (2018) Trends in prevalence and control of hypertension according to the 2017 American college of cardiology/American heart association (ACC/AHA) Guideline

    Journal of the American Heart Association 7:e008888.

    https://doi.org/10.1161/JAHA.118.008888

    • PubMed
    • Google Scholar
21. 1. Ettehad D
    2. Emdin CA
    3. Kiran A
    4. Anderson SG
    5. Callender T
    6. Emberson J
    7. Chalmers J
    8. Rodgers A
    9. Rahimi K

    (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis

    The Lancet 387:957–967.

    https://doi.org/10.1016/S0140-6736(15)01225-8

    • Google Scholar
22. 1. Franssen EJF
    2. Moolenaar F
    3. de Zeeuw D
    4. Meijer DKF

    (1994) Drug targeting to the kidney with low-molecular-weight proteins

    Advanced Drug Delivery Reviews 14:67–88.

    https://doi.org/10.1016/0169-409X(94)90006-X

    • Google Scholar
23. 1. Fung K
    2. Ramírez J
    3. Warren HR
    4. Aung N
    5. Lee AM
    6. Tzanis E
    7. Petersen SE
    8. Munroe PB

    (2019) Genome-wide association study identifies loci for arterial stiffness index in 127,121 UK biobank participants

    Scientific Reports 9:9143.

    https://doi.org/10.1038/s41598-019-45703-0

    • PubMed
    • Google Scholar
24. 1. Gomolak JR
    2. Didion SP

    (2014) Angiotensin II-induced endothelial dysfunction is temporally linked with increases in interleukin-6 and vascular macrophage accumulation

    Frontiers in Physiology 5:396.

    https://doi.org/10.3389/fphys.2014.00396

    • PubMed
    • Google Scholar
25. 1. Henri O
    2. Pouehe C
    3. Houssari M
    4. Galas L
    5. Nicol L
    6. Edwards-Lévy F
    7. Henry J-P
    8. Dumesnil A
    9. Boukhalfa I
    10. Banquet S
    11. Schapman D
    12. Thuillez C
    13. Richard V
    14. Mulder P
    15. Brakenhielm E

    (2016) Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction

    Circulation 133:1484–1497.

    https://doi.org/10.1161/CIRCULATIONAHA.115.020143

    • Google Scholar
26. 1. Houssari M
    2. Dumesnil A
    3. Tardif V
    4. Kivelä R
    5. Pizzinat N
    6. Boukhalfa I
    7. Godefroy D
    8. Schapman D
    9. Hemanthakumar KA
    10. Bizou M
    11. Henry JP
    12. Renet S
    13. Riou G
    14. Rondeaux J
    15. Anouar Y
    16. Adriouch S
    17. Fraineau S
    18. Alitalo K
    19. Richard V
    20. Mulder P
    21. Brakenhielm E

    (2020) Lymphatic and immune cell Cross-Talk regulates cardiac recovery after experimental myocardial infarction

    Arteriosclerosis, Thrombosis, and Vascular Biology 40:1722–1737.

    https://doi.org/10.1161/ATVBAHA.120.314370

    • PubMed
    • Google Scholar
27. 1. Huang LH
    2. Lavine KJ
    3. Randolph GJ

    (2017) Cardiac lymphatic vessels, transport, and healing of the infarcted heart

    JACC: Basic to Translational Science 2:477–483.

    https://doi.org/10.1016/j.jacbts.2017.02.005

    • PubMed
    • Google Scholar
28. 1. Johansson A
    2. Marroni F
    3. Hayward C
    4. Franklin CS
    5. Kirichenko AV
    6. Jonasson I
    7. Hicks AA
    8. Vitart V
    9. Isaacs A
    10. Axenovich T
    11. Campbell S
    12. Floyd J
    13. Hastie N
    14. Knott S
    15. Lauc G
    16. Pichler I
    17. Rotim K
    18. Wild SH
    19. Zorkoltseva IV
    20. Wilson JF
    21. Rudan I
    22. Campbell H
    23. Pattaro C
    24. Pramstaller P
    25. Oostra BA
    26. Wright AF
    27. van Duijn CM
    28. Aulchenko YS
    29. Gyllensten U
    30. EUROSPAN Consortium

    (2010) Linkage and Genome-wide Association analysis of Obesity-related phenotypes: association of weight with the MGAT1 Gene

    Obesity 18:803–808.

    https://doi.org/10.1038/oby.2009.359

    • PubMed
    • Google Scholar
29. 1. Joukov V
    2. Kumar V
    3. Sorsa T
    4. Arighi E
    5. Weich H
    6. Saksela O
    7. Alitalo K

    (1998) A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities

    Journal of Biological Chemistry 273:6599–6602.

    https://doi.org/10.1074/jbc.273.12.6599

    • PubMed
    • Google Scholar
30. 1. justice AE
    2. Karaderi T
    3. Highland HM
    4. Young KL
    5. Graff M
    6. Lu Y
    7. Turcot V
    8. Auer PL
    9. Fine RS
    10. Guo X
    11. Schurmann C
    12. Lempradl A
    13. Marouli E
    14. Mahajan A
    15. Winkler TW
    16. Locke AE
    17. Medina-Gomez C
    18. Esko T
    19. Vedantam S
    20. Giri A
    21. Lo KS
    22. Alfred T
    23. Mudgal P
    24. Ng MCY
    25. Heard-Costa NL
    26. Feitosa MF
    27. Manning AK
    28. Willems SM
    29. Sivapalaratnam S
    30. Abecasis G
    31. Alam DS
    32. Allison M
    33. Amouyel P
    34. Arzumanyan Z
    35. Balkau B
    36. Bastarache L
    37. Bergmann S
    38. Bielak LF
    39. Blüher M
    40. Boehnke M
    41. Boeing H
    42. Boerwinkle E
    43. Böger CA
    44. Bork-Jensen J
    45. Bottinger EP
    46. Bowden DW
    47. Brandslund I
    48. Broer L
    49. Burt AA
    50. Butterworth AS
    51. Caulfield MJ
    52. Cesana G
    53. Chambers JC
    54. Chasman DI
    55. Chen YI
    56. Chowdhury R
    57. Christensen C
    58. Chu AY
    59. Collins FS
    60. Cook JP
    61. Cox AJ
    62. Crosslin DS
    63. Danesh J
    64. de Bakker PIW
    65. Denus S
    66. Mutsert R
    67. Dedoussis G
    68. Demerath EW
    69. Dennis JG
    70. Denny JC
    71. Di Angelantonio E
    72. Dörr M
    73. Drenos F
    74. Dubé MP
    75. Dunning AM
    76. Easton DF
    77. Elliott P
    78. Evangelou E
    79. Farmaki AE
    80. Feng S
    81. Ferrannini E
    82. Ferrieres J
    83. Florez JC
    84. Fornage M
    85. Fox CS
    86. Franks PW
    87. Friedrich N
    88. Gan W
    89. Gandin I
    90. Gasparini P
    91. Giedraitis V
    92. Girotto G
    93. Gorski M
    94. Grallert H
    95. Grarup N
    96. Grove ML
    97. Gustafsson S
    98. Haessler J
    99. Hansen T
    100. Hattersley AT
    101. Hayward C
    102. Heid IM
    103. Holmen OL
    104. Hovingh GK
    105. Howson JMM
    106. Hu Y
    107. Hung YJ
    108. Hveem K
    109. Ikram MA
    110. Ingelsson E
    111. Jackson AU
    112. Jarvik GP
    113. Jia Y
    114. Jørgensen T
    115. Jousilahti P
    116. Justesen JM
    117. Kahali B
    118. Karaleftheri M
    119. Kardia SLR
    120. Karpe F
    121. Kee F
    122. Kitajima H
    123. Komulainen P
    124. Kooner JS
    125. Kovacs P
    126. Krämer BK
    127. Kuulasmaa K
    128. Kuusisto J
    129. Laakso M
    130. Lakka TA
    131. Lamparter D
    132. Lange LA
    133. Langenberg C
    134. Larson EB
    135. Lee NR
    136. Lee WJ
    137. Lehtimäki T
    138. Lewis CE
    139. Li H
    140. Li J
    141. Li-Gao R
    142. Lin LA
    143. Lin X
    144. Lind L
    145. Lindström J
    146. Linneberg A
    147. Liu CT
    148. Liu DJ
    149. Luan J
    150. Lyytikäinen LP
    151. MacGregor S
    152. Mägi R
    153. Männistö S
    154. Marenne G
    155. Marten J
    156. Masca NGD
    157. McCarthy MI
    158. Meidtner K
    159. Mihailov E
    160. Moilanen L
    161. Moitry M
    162. Mook-Kanamori DO
    163. Morgan A
    164. Morris AP
    165. Müller-Nurasyid M
    166. Munroe PB
    167. Narisu N
    168. Nelson CP
    169. Neville M
    170. Ntalla I
    171. O'Connell JR
    172. Owen KR
    173. Pedersen O
    174. Peloso GM
    175. Pennell CE
    176. Perola M
    177. Perry JA
    178. Perry JRB
    179. Pers TH
    180. Ewing A
    181. Polasek O
    182. Raitakari OT
    183. Rasheed A
    184. Raulerson CK
    185. Rauramaa R
    186. Reilly DF
    187. Reiner AP
    188. Ridker PM
    189. Rivas MA
    190. Robertson NR
    191. Robino A
    192. Rudan I
    193. Ruth KS
    194. Saleheen D
    195. Salomaa V
    196. Samani NJ
    197. Schreiner PJ
    198. Schulze MB
    199. Scott RA
    200. Segura-Lepe M
    201. Sim X
    202. Slater AJ
    203. Small KS
    204. Smith BH
    205. Smith JA
    206. Southam L
    207. Spector TD
    208. Speliotes EK
    209. Stefansson K
    210. Steinthorsdottir V
    211. Stirrups KE
    212. Strauch K
    213. Stringham HM
    214. Stumvoll M
    215. Sun L
    216. Surendran P
    217. Swart KMA
    218. Tardif JC
    219. Taylor KD
    220. Teumer A
    221. Thompson DJ
    222. Thorleifsson G
    223. Thorsteinsdottir U
    224. Thuesen BH
    225. Tönjes A
    226. Torres M
    227. Tsafantakis E
    228. Tuomilehto J
    229. Uitterlinden AG
    230. Uusitupa M
    231. van Duijn CM
    232. Vanhala M
    233. Varma R
    234. Vermeulen SH
    235. Vestergaard H
    236. Vitart V
    237. Vogt TF
    238. Vuckovic D
    239. Wagenknecht LE
    240. Walker M
    241. Wallentin L
    242. Wang F
    243. Wang CA
    244. Wang S
    245. Wareham NJ
    246. Warren HR
    247. Waterworth DM
    248. Wessel J
    249. White HD
    250. Willer CJ
    251. Wilson JG
    252. Wood AR
    253. Wu Y
    254. Yaghootkar H
    255. Yao J
    256. Yerges-Armstrong LM
    257. Young R
    258. Zeggini E
    259. Zhan X
    260. Zhang W
    261. Zhao JH
    262. Zhao W
    263. Zheng H
    264. Zhou W
    265. Zillikens MC
    266. Rivadeneira F
    267. Borecki IB
    268. Pospisilik JA
    269. Deloukas P
    270. Frayling TM
    271. Lettre G
    272. Mohlke KL
    273. Rotter JI
    274. Kutalik Z
    275. Hirschhorn JN
    276. Cupples LA
    277. Loos RJF
    278. North KE
    279. Lindgren CM
    280. CHD Exome+ Consortium
    281. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium
    282. EPIC-CVD Consortium
    283. ExomeBP Consortium
    284. Global Lipids Genetic Consortium
    285. GoT2D Genes Consortium
    286. InterAct
    287. ReproGen Consortium
    288. T2D-Genes Consortium
    289. MAGIC Investigators

    (2019) Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution

    Nature Genetics 51:452–469.

    https://doi.org/10.1038/s41588-018-0334-2

    • PubMed
    • Google Scholar
31. 1. Karlsen TV
    2. Nikpey E
    3. Han J
    4. Reikvam T
    5. Rakova N
    6. Castorena-Gonzalez JA
    7. Davis MJ
    8. Titze JM
    9. Tenstad O
    10. Wiig H

    (2018) High-Salt diet causes expansion of the lymphatic network and increased lymph flow in skin and muscle of rats

    Arteriosclerosis, Thrombosis, and Vascular Biology 38:2054–2064.

    https://doi.org/10.1161/ATVBAHA.118.311149

    • PubMed
    • Google Scholar
32. 1. Kettunen J
    2. Demirkan A
    3. Würtz P
    4. Draisma HH
    5. Haller T
    6. Rawal R
    7. Vaarhorst A
    8. Kangas AJ
    9. Lyytikäinen LP
    10. Pirinen M
    11. Pool R
    12. Sarin AP
    13. Soininen P
    14. Tukiainen T
    15. Wang Q
    16. Tiainen M
    17. Tynkkynen T
    18. Amin N
    19. Zeller T
    20. Beekman M
    21. Deelen J
    22. van Dijk KW
    23. Esko T
    24. Hottenga JJ
    25. van Leeuwen EM
    26. Lehtimäki T
    27. Mihailov E
    28. Rose RJ
    29. de Craen AJ
    30. Gieger C
    31. Kähönen M
    32. Perola M
    33. Blankenberg S
    34. Savolainen MJ
    35. Verhoeven A
    36. Viikari J
    37. Willemsen G
    38. Boomsma DI
    39. van Duijn CM
    40. Eriksson J
    41. Jula A
    42. Järvelin MR
    43. Kaprio J
    44. Metspalu A
    45. Raitakari O
    46. Salomaa V
    47. Slagboom PE
    48. Waldenberger M
    49. Ripatti S
    50. Ala-Korpela M

    (2016) Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA

    Nature Communications 7:11122.

    https://doi.org/10.1038/ncomms11122

    • PubMed
    • Google Scholar
33. 1. Kichaev G
    2. Bhatia G
    3. Loh PR
    4. Gazal S
    5. Burch K
    6. Freund MK
    7. Schoech A
    8. Pasaniuc B
    9. Price AL

    (2019) Leveraging polygenic functional enrichment to improve GWAS power

    The American Journal of Human Genetics 104:65–75.

    https://doi.org/10.1016/j.ajhg.2018.11.008

    • PubMed
    • Google Scholar
34. Book

    1. King KC
    2. Goldstein S

    (2020)

    Congestive Heart Failure and Pulmonary Edema

    Treasure Island: StatPearls Publishing.

    • Google Scholar
35. 1. Klotz L
    2. Norman S
    3. Vieira JM
    4. Masters M
    5. Rohling M
    6. Dubé KN
    7. Bollini S
    8. Matsuzaki F
    9. Carr CA
    10. Riley PR

    (2015) Cardiac lymphatics are heterogeneous in origin and respond to injury

    Nature 522:62–67.

    https://doi.org/10.1038/nature14483

    • PubMed
    • Google Scholar
36. 1. Liu X
    2. Oliver G

    (2019) New insights about the lymphatic vasculature in cardiovascular diseases

    F1000Research 8:1811.

    https://doi.org/10.12688/f1000research.20107.1

    • Google Scholar
37. 1. Lopez Gelston CA
    2. Balasubbramanian D
    3. Abouelkheir GR
    4. Lopez AH
    5. Hudson KR
    6. Johnson ER
    7. Muthuchamy M
    8. Mitchell BM
    9. Rutkowski JM

    (2018) Enhancing renal lymphatic expansion prevents hypertension in mice

    Circulation Research 122:1094–1101.

    https://doi.org/10.1161/CIRCRESAHA.118.312765

    • PubMed
    • Google Scholar
38. 1. Lotta LA
    2. Wittemans LBL
    3. Zuber V
    4. Stewart ID
    5. Sharp SJ
    6. Luan J
    7. Day FR
    8. Li C
    9. Bowker N
    10. Cai L
    11. De Lucia Rolfe E
    12. Khaw KT
    13. Perry JRB
    14. O'Rahilly S
    15. Scott RA
    16. Savage DB
    17. Burgess S
    18. Wareham NJ
    19. Langenberg C

    (2018) Association of genetic variants related to gluteofemoral vs abdominal fat distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors

    Jama 320:2553–2563.

    https://doi.org/10.1001/jama.2018.19329

    • PubMed
    • Google Scholar
39. 1. Lu X
    2. Peloso GM
    3. Liu DJ
    4. Wu Y
    5. Zhang H
    6. Zhou W
    7. Li J
    8. Tang CS
    9. Dorajoo R
    10. Li H
    11. Long J
    12. Guo X
    13. Xu M
    14. Spracklen CN
    15. Chen Y
    16. Liu X
    17. Zhang Y
    18. Khor CC
    19. Liu J
    20. Sun L
    21. Wang L
    22. Gao YT
    23. Hu Y
    24. Yu K
    25. Wang Y
    26. Cheung CYY
    27. Wang F
    28. Huang J
    29. Fan Q
    30. Cai Q
    31. Chen S
    32. Shi J
    33. Yang X
    34. Zhao W
    35. Sheu WH
    36. Cherny SS
    37. He M
    38. Feranil AB
    39. Adair LS
    40. Gordon-Larsen P
    41. Du S
    42. Varma R
    43. Chen YI
    44. Shu XO
    45. Lam KSL
    46. Wong TY
    47. Ganesh SK
    48. Mo Z
    49. Hveem K
    50. Fritsche LG
    51. Nielsen JB
    52. Tse HF
    53. Huo Y
    54. Cheng CY
    55. Chen YE
    56. Zheng W
    57. Tai ES
    58. Gao W
    59. Lin X
    60. Huang W
    61. Abecasis G
    62. Kathiresan S
    63. Mohlke KL
    64. Wu T
    65. Sham PC
    66. Gu D
    67. Willer CJ
    68. GLGC Consortium

    (2017) Exome chip meta-analysis identifies novel loci and east Asian-specific coding variants that contribute to lipid levels and coronary artery disease

    Nature Genetics 49:1722–1730.

    https://doi.org/10.1038/ng.3978

    • PubMed
    • Google Scholar
40. 1. Mazzolai L
    2. Pedrazzini T
    3. Nicoud F
    4. Gabbiani G
    5. Brunner HR
    6. Nussberger J

    (2000) Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice

    Hypertension 35:985–991.

    https://doi.org/10.1161/01.HYP.35.4.985

    • PubMed
    • Google Scholar
41. 1. Mehlhorn U
    2. Davis KL
    3. Burke EJ
    4. Adams D
    5. Laine GA
    6. Allen SJ

    (1995) Impact of cardiopulmonary bypass and cardioplegic arrest on myocardial lymphatic function

    American Journal of Physiology-Heart and Circulatory Physiology 268:H178–H183.

    https://doi.org/10.1152/ajpheart.1995.268.1.H178

    • Google Scholar
42. 1. Mehta PK
    2. Griendling KK

    (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

    American Journal of Physiology-Cell Physiology 292:C82–C97.

    https://doi.org/10.1152/ajpcell.00287.2006

    • PubMed
    • Google Scholar
43. Preprint

    1. Nasa Sinnott-Armstrong YT
    2. Amar Mars DD
    3. Aguirre M

    (2019) Genetics of 38 blood and urine biomarkers in the UK biobank

    bioRxiv.

    https://doi.org/10.1101/660506

    • Google Scholar
44. 1. Norrmén C
    2. Tammela T
    3. Petrova TV
    4. Alitalo K

    (2011) Biological basis of therapeutic lymphangiogenesis

    Circulation 123:1335–1351.

    https://doi.org/10.1161/CIRCULATIONAHA.107.704098

    • PubMed
    • Google Scholar
45. 1. Oliver G
    2. Kipnis J
    3. Randolph GJ
    4. Harvey NL

    (2020) The lymphatic vasculature in the 21^st Century: Novel Functional Roles in Homeostasis and Disease

    Cell 182:270–296.

    https://doi.org/10.1016/j.cell.2020.06.039

    • PubMed
    • Google Scholar
46. 1. Pertl C
    2. Eblenkamp M
    3. Pertl A
    4. Pfeifer S
    5. Wintermantel E
    6. Lochmüller H
    7. Walter MC
    8. Krause S
    9. Thirion C

    (2013) A new web-based method for automated analysis of muscle histology

    BMC Musculoskeletal Disorders 14:26.

    https://doi.org/10.1186/1471-2474-14-26

    • PubMed
    • Google Scholar
47. 1. Quintanilla M
    2. Montero-Montero L
    3. Renart J
    4. Martín-Villar E

    (2019) Podoplanin in inflammation and Cancer

    International Journal of Molecular Sciences 20:707.

    https://doi.org/10.3390/ijms20030707

    • PubMed
    • Google Scholar
48. 1. Saxena R
    2. Hivert MF
    3. Langenberg C
    4. Tanaka T
    5. Pankow JS
    6. Vollenweider P
    7. Lyssenko V
    8. Bouatia-Naji N
    9. Dupuis J
    10. Jackson AU
    11. Kao WH
    12. Li M
    13. Glazer NL
    14. Manning AK
    15. Luan J
    16. Stringham HM
    17. Prokopenko I
    18. Johnson T
    19. Grarup N
    20. Boesgaard TW
    21. Lecoeur C
    22. Shrader P
    23. O'Connell J
    24. Ingelsson E
    25. Couper DJ
    26. Rice K
    27. Song K
    28. Andreasen CH
    29. Dina C
    30. Köttgen A
    31. Le Bacquer O
    32. Pattou F
    33. Taneera J
    34. Steinthorsdottir V
    35. Rybin D
    36. Ardlie K
    37. Sampson M
    38. Qi L
    39. van Hoek M
    40. Weedon MN
    41. Aulchenko YS
    42. Voight BF
    43. Grallert H
    44. Balkau B
    45. Bergman RN
    46. Bielinski SJ
    47. Bonnefond A
    48. Bonnycastle LL
    49. Borch-Johnsen K
    50. Böttcher Y
    51. Brunner E
    52. Buchanan TA
    53. Bumpstead SJ
    54. Cavalcanti-Proença C
    55. Charpentier G
    56. Chen YD
    57. Chines PS
    58. Collins FS
    59. Cornelis M
    60. J Crawford G
    61. Delplanque J
    62. Doney A
    63. Egan JM
    64. Erdos MR
    65. Firmann M
    66. Forouhi NG
    67. Fox CS
    68. Goodarzi MO
    69. Graessler J
    70. Hingorani A
    71. Isomaa B
    72. Jørgensen T
    73. Kivimaki M
    74. Kovacs P
    75. Krohn K
    76. Kumari M
    77. Lauritzen T
    78. Lévy-Marchal C
    79. Mayor V
    80. McAteer JB
    81. Meyre D
    82. Mitchell BD
    83. Mohlke KL
    84. Morken MA
    85. Narisu N
    86. Palmer CN
    87. Pakyz R
    88. Pascoe L
    89. Payne F
    90. Pearson D
    91. Rathmann W
    92. Sandbaek A
    93. Sayer AA
    94. Scott LJ
    95. Sharp SJ
    96. Sijbrands E
    97. Singleton A
    98. Siscovick DS
    99. Smith NL
    100. Sparsø T
    101. Swift AJ
    102. Syddall H
    103. Thorleifsson G
    104. Tönjes A
    105. Tuomi T
    106. Tuomilehto J
    107. Valle TT
    108. Waeber G
    109. Walley A
    110. Waterworth DM
    111. Zeggini E
    112. Zhao JH
    113. Illig T
    114. Wichmann HE
    115. Wilson JF
    116. van Duijn C
    117. Hu FB
    118. Morris AD
    119. Frayling TM
    120. Hattersley AT
    121. Thorsteinsdottir U
    122. Stefansson K
    123. Nilsson P
    124. Syvänen AC
    125. Shuldiner AR
    126. Walker M
    127. Bornstein SR
    128. Schwarz P
    129. Williams GH
    130. Nathan DM
    131. Kuusisto J
    132. Laakso M
    133. Cooper C
    134. Marmot M
    135. Ferrucci L
    136. Mooser V
    137. Stumvoll M
    138. Loos RJ
    139. Altshuler D
    140. Psaty BM
    141. Rotter JI
    142. Boerwinkle E
    143. Hansen T
    144. Pedersen O
    145. Florez JC
    146. McCarthy MI
    147. Boehnke M
    148. Barroso I
    149. Sladek R
    150. Froguel P
    151. Meigs JB
    152. Groop L
    153. Wareham NJ
    154. Watanabe RM
    155. GIANT consortium
    156. MAGIC investigators

    (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge

    Nature Genetics 42:142–148.

    https://doi.org/10.1038/ng.521

    • PubMed
    • Google Scholar
49. 1. Shimizu Y
    2. Polavarapu R
    3. Eskla KL
    4. Pantner Y
    5. Nicholson CK
    6. Ishii M
    7. Brunnhoelzl D
    8. Mauria R
    9. Husain A
    10. Naqvi N
    11. Murohara T
    12. Calvert JW

    (2018) Impact of lymphangiogenesis on cardiac remodeling after ischemia and reperfusion injury

    Journal of the American Heart Association 7:e009565.

    https://doi.org/10.1161/JAHA.118.009565

    • PubMed
    • Google Scholar
50. 1. Suzuki Y
    2. Ruiz-Ortega M
    3. Lorenzo O
    4. Ruperez M
    5. Esteban V
    6. Egido J

    (2003) Inflammation and angiotensin II

    The International Journal of Biochemistry & Cell Biology 35:881–900.

    https://doi.org/10.1016/S1357-2725(02)00271-6

    • PubMed
    • Google Scholar
51. 1. Sweet ME
    2. Cocciolo A
    3. Slavov D
    4. Jones KL
    5. Sweet JR
    6. Graw SL
    7. Reece TB
    8. Ambardekar AV
    9. Bristow MR
    10. Mestroni L
    11. Taylor MRG

    (2018) Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure

    BMC Genomics 19:812.

    https://doi.org/10.1186/s12864-018-5213-9

    • PubMed
    • Google Scholar
52. Book

    1. Tackling G
    2. Borhade MB

    (2019)

    Hypertensive Heart Disease

    Treasure Island: StatPearls.

    • Google Scholar
53. 1. Tammela T
    2. Saaristo A
    3. Holopainen T
    4. Lyytikkä J
    5. Kotronen A
    6. Pitkonen M
    7. Abo-Ramadan U
    8. Ylä-Herttuala S
    9. Petrova TV
    10. Alitalo K

    (2007) Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation

    Nature Medicine 13:1458–1466.

    https://doi.org/10.1038/nm1689

    • PubMed
    • Google Scholar
54. 1. Tatin F
    2. Renaud-Gabardos E
    3. Godet AC
    4. Hantelys F
    5. Pujol F
    6. Morfoisse F
    7. Calise D
    8. Viars F
    9. Valet P
    10. Masri B
    11. Prats AC
    12. Garmy-Susini B

    (2017) Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarction

    JCI Insight 2:93887.

    https://doi.org/10.1172/jci.insight.93887

    • PubMed
    • Google Scholar
55. 1. Trincot CE
    2. Xu W
    3. Zhang H
    4. Kulikauskas MR
    5. Caranasos TG
    6. Jensen BC
    7. Sabine A
    8. Petrova TV
    9. Caron KM

    (2019) Adrenomedullin induces cardiac lymphangiogenesis after myocardial infarction and regulates cardiac edema via connexin 43

    Circulation Research 124:101–113.

    https://doi.org/10.1161/CIRCRESAHA.118.313835

    • PubMed
    • Google Scholar
56. 1. van der Harst P
    2. Verweij N

    (2018) Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease

    Circulation Research 122:433–443.

    https://doi.org/10.1161/CIRCRESAHA.117.312086

    • PubMed
    • Google Scholar
57. 1. van Heesch S
    2. Witte F
    3. Schneider-Lunitz V
    4. Schulz JF
    5. Adami E
    6. Faber AB
    7. Kirchner M
    8. Maatz H
    9. Blachut S
    10. Sandmann C-L
    11. Kanda M
    12. Worth CL
    13. Schafer S
    14. Calviello L
    15. Merriott R
    16. Patone G
    17. Hummel O
    18. Wyler E
    19. Obermayer B
    20. Mücke MB
    21. Lindberg EL
    22. Trnka F
    23. Memczak S
    24. Schilling M
    25. Felkin LE
    26. Barton PJR
    27. Quaife NM
    28. Vanezis K
    29. Diecke S
    30. Mukai M
    31. Mah N
    32. Oh S-J
    33. Kurtz A
    34. Schramm C
    35. Schwinge D
    36. Sebode M
    37. Harakalova M
    38. Asselbergs FW
    39. Vink A
    40. de Weger RA
    41. Viswanathan S
    42. Widjaja AA
    43. Gärtner-Rommel A
    44. Milting H
    45. dos Remedios C
    46. Knosalla C
    47. Mertins P
    48. Landthaler M
    49. Vingron M
    50. Linke WA
    51. Seidman JG
    52. Seidman CE
    53. Rajewsky N
    54. Ohler U
    55. Cook SA
    56. Hubner N

    (2019) The translational landscape of the human heart

    Cell 178:242–260.

    https://doi.org/10.1016/j.cell.2019.05.010

    • Google Scholar
58. 1. Vieira JM
    2. Norman S
    3. Villa Del Campo C
    4. Cahill TJ
    5. Barnette DN
    6. Gunadasa-Rohling M
    7. Johnson LA
    8. Greaves DR
    9. Carr CA
    10. Jackson DG
    11. Riley PR

    (2018) The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction

    Journal of Clinical Investigation 128:3402–3412.

    https://doi.org/10.1172/JCI97192

    • PubMed
    • Google Scholar
59. 1. Vivien CJ
    2. Pichol-Thievend C
    3. Sim CB
    4. Smith JB
    5. Bower NI
    6. Hogan BM
    7. Hudson JE
    8. Francois M
    9. Porrello ER

    (2019) Vegfc/d-dependent regulation of the lymphatic vasculature during cardiac regeneration is influenced by injury context

    npj Regenerative Medicine 4:18.

    https://doi.org/10.1038/s41536-019-0079-2

    • Google Scholar
60. 1. Wada H
    2. Suzuki M
    3. Matsuda M
    4. Ajiro Y
    5. Shinozaki T
    6. Sakagami S
    7. Yonezawa K
    8. Shimizu M
    9. Funada J
    10. Takenaka T
    11. Morita Y
    12. Nakamura T
    13. Fujimoto K
    14. Matsubara H
    15. Kato T
    16. Unoki T
    17. Takagi D
    18. Ura S
    19. Wada K
    20. Iguchi M
    21. Masunaga N
    22. Ishii M
    23. Yamakage H
    24. Shimatsu A
    25. Kotani K
    26. Satoh-Asahara N
    27. Abe M
    28. Akao M
    29. Hasegawa K
    30. ANOX Study Investigators

    (2018) VEGF-C and mortality in patients with suspected or known coronary artery disease

    Journal of the American Heart Association 7:e010355.

    https://doi.org/10.1161/JAHA.118.010355

    • PubMed
    • Google Scholar
61. 1. Watanabe T
    2. Barker TA
    3. Berk BC

    (2005) Angiotensin II and the endothelium: diverse signals and effects

    Hypertension 45:163–169.

    https://doi.org/10.1161/01.HYP.0000153321.13792.b9

    • PubMed
    • Google Scholar
62. 1. Wild PS
    2. Felix JF
    3. Schillert A
    4. Teumer A
    5. Chen MH
    6. Leening MJG
    7. Völker U
    8. Großmann V
    9. Brody JA
    10. Irvin MR
    11. Shah SJ
    12. Pramana S
    13. Lieb W
    14. Schmidt R
    15. Stanton AV
    16. Malzahn D
    17. Smith AV
    18. Sundström J
    19. Minelli C
    20. Ruggiero D
    21. Lyytikäinen LP
    22. Tiller D
    23. Smith JG
    24. Monnereau C
    25. Di Tullio MR
    26. Musani SK
    27. Morrison AC
    28. Pers TH
    29. Morley M
    30. Kleber ME
    31. Aragam J
    32. Benjamin EJ
    33. Bis JC
    34. Bisping E
    35. Broeckel U
    36. Cheng S
    37. Deckers JW
    38. Del Greco M F
    39. Edelmann F
    40. Fornage M
    41. Franke L
    42. Friedrich N
    43. Harris TB
    44. Hofer E
    45. Hofman A
    46. Huang J
    47. Hughes AD
    48. Kähönen M
    49. Investigators K
    50. Kruppa J
    51. Lackner KJ
    52. Lannfelt L
    53. Laskowski R
    54. Launer LJ
    55. Leosdottir M
    56. Lin H
    57. Lindgren CM
    58. Loley C
    59. MacRae CA
    60. Mascalzoni D
    61. Mayet J
    62. Medenwald D
    63. Morris AP
    64. Müller C
    65. Müller-Nurasyid M
    66. Nappo S
    67. Nilsson PM
    68. Nuding S
    69. Nutile T
    70. Peters A
    71. Pfeufer A
    72. Pietzner D
    73. Pramstaller PP
    74. Raitakari OT
    75. Rice KM
    76. Rivadeneira F
    77. Rotter JI
    78. Ruohonen ST
    79. Sacco RL
    80. Samdarshi TE
    81. Schmidt H
    82. Sharp ASP
    83. Shields DC
    84. Sorice R
    85. Sotoodehnia N
    86. Stricker BH
    87. Surendran P
    88. Thom S
    89. Töglhofer AM
    90. Uitterlinden AG
    91. Wachter R
    92. Völzke H
    93. Ziegler A
    94. Münzel T
    95. März W
    96. Cappola TP
    97. Hirschhorn JN
    98. Mitchell GF
    99. Smith NL
    100. Fox ER
    101. Dueker ND
    102. Jaddoe VWV
    103. Melander O
    104. Russ M
    105. Lehtimäki T
    106. Ciullo M
    107. Hicks AA
    108. Lind L
    109. Gudnason V
    110. Pieske B
    111. Barron AJ
    112. Zweiker R
    113. Schunkert H
    114. Ingelsson E
    115. Liu K
    116. Arnett DK
    117. Psaty BM
    118. Blankenberg S
    119. Larson MG
    120. Felix SB
    121. Franco OH
    122. Zeller T
    123. Vasan RS
    124. Dörr M

    (2017) Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function

    Journal of Clinical Investigation 127:1798–1812.

    https://doi.org/10.1172/JCI84840

    • PubMed
    • Google Scholar
63. 1. Xu H
    2. Dorn GW
    3. Shetty A
    4. Parihar A
    5. Dave T
    6. Robinson SW
    7. Gottlieb SS
    8. Donahue MP
    9. Tomaselli GF
    10. Kraus WE
    11. Mitchell BD
    12. Liggett SB

    (2018) A Genome-Wide association study of idiopathic dilated cardiomyopathy in african americans

    Journal of Personalized Medicine 8:11.

    https://doi.org/10.3390/jpm8010011

    • PubMed
    • Google Scholar

Author details

1. LouJin Song

   Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States

   Contribution

   Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Writing - original draft, Writing - review and editing

   Competing interests

   is an employee at Pfizer inc

   "This ORCID iD identifies the author of this article:" 0000-0002-1646-8121

2. Xian Chen

   1. Comparative Medicine, Pfizer Inc, Cambridge, United States
   2. Drug Safety Research & Development, Pfizer Inc, Groton, United States

   Contribution

   Investigation

   Competing interests

   is an employee at Pfizer inc

3. Terri A Swanson

   Early Clinical Development, Pfizer Inc, Cambridge, United States

   Contribution

   Investigation

   Competing interests

   is an employee at Pfizer inc

4. Brianna LaViolette

   Comparative Medicine, Pfizer Inc, Cambridge, United States

   Contribution

   Investigation

   Competing interests

   is an employee at Pfizer inc

5. Jincheng Pang

   Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States

   Contribution

   Formal analysis, Methodology

   Competing interests

   is an employee at Pfizer inc

6. Teresa Cunio

   1. Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States
   2. Acceleron Pharma, Cambridge, United States

   Present address

   Acceleron Pharmaceuticals

   Contribution

   Investigation

   Competing interests

   was an employee at Pfizer inc and is currently an employee at Acceleron Pharma

7. Michael W Nagle

   1. Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States
   2. Eisai Inc, Cambridge, United States

   Present address

   Eisai Pharmaceuticals

   Contribution

   Formal analysis, Methodology, Writing - review and editing

   Competing interests

   was an employee at Pfizer Inc and is currently an employee at Eisai Inc

8. Shoh Asano

   Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States

   Contribution

   Investigation

   Competing interests

   is an employee at Pfizer Inc

9. Katherine Hales

   Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States

   Contribution

   Investigation

   Competing interests

   is an employee at Pfizer Inc

10. Arun Shipstone

    Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, United States

    Contribution

    Investigation, Methodology

    Competing interests

    is an employee at Pfizer Inc

11. Hanna Sobon

    Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, United States

    Contribution

    Investigation, Methodology

    Competing interests

    is an employee at Pfizer Inc

12. Sabra D Al-Harthy

    1. Comparative Medicine, Pfizer Inc, Cambridge, United States
    2. Drug Safety Research & Development, Pfizer Inc, Groton, United States

    Contribution

    Investigation

    Competing interests

    is an employee at Pfizer Inc

13. Youngwook Ahn

    Target Sciences, Emerging Science and Innovation, Pfizer Inc, Cambridge, United States

    Contribution

    Investigation, Methodology

    Competing interests

    is an employee at Pfizer Inc

14. Steven Kreuser

    Comparative Medicine, Pfizer Inc, Cambridge, United States

    Contribution

    Investigation

    Competing interests

    is an employee at Pfizer Inc

15. Andrew Robertson

    Drug Safety Research & Development, Pfizer Inc, Groton, United States

    Contribution

    Investigation

    Competing interests

    is an employee at Pfizer Inc

16. Casey Ritenour

    Drug Safety Research & Development, Pfizer Inc, Groton, United States

    Contribution

    Investigation

    Competing interests

    is an employee at Pfizer Inc

17. Frank Voigt

    Drug Safety Research & Development, Pfizer Inc, Groton, United States

    Contribution

    Investigation

    Competing interests

    is an employee at Pfizer Inc

18. Magalie Boucher

    Drug Safety Research & Development, Pfizer Inc, Groton, United States

    Contribution

    Investigation

    Competing interests

    is an employee at Pfizer Inc

19. Furong Sun

    Early Clinical Development, Pfizer Inc, Cambridge, United States

    Contribution

    Formal analysis

    Competing interests

    is an employee at Pfizer Inc

20. William C Sessa

    Department of Pharmacology, Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, United States

    Contribution

    Supervision, Visualization, Writing - review and editing

    Competing interests

    consultant for Pfizer.

    "This ORCID iD identifies the author of this article:" 0000-0001-5759-1938

21. Rachel J Roth Flach

    Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States

    Contribution

    Conceptualization, Supervision, Funding acquisition, Visualization, Project administration, Writing - review and editing

    For correspondence

    Rachel.RothFlach@pfizer.com

    Competing interests

    is an employee at Pfizer Inc

    "This ORCID iD identifies the author of this article:" 0000-0003-2754-828X

• 2,619

  views

• 310

  downloads

• 34

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.